Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen

Hepatology

Volumn 66, Issue 4, 2017, Pages 1083-1089

  Gane, Edward J ^a   Shiffman, Mitchell L ^b   Etzkorn, Kyle ^c   Morelli, Giuseppe ^d   Stedman, Catherine A M ^e   Davis, Mitchell N ^f   Hinestrosa, Federico ^g   Dvory Sobol, Hadas ^h   Huang, K C ^h   Osinusi, Anu ^h   McNally, John ^h   Brainard, Diana M ^h   McHutchison, John G ^h   Thompson, Alex J ⁱ   Sulkowski, Mark S ^j  

^a Auckland Clinical Studies   (New Zealand)

^b Liver Institute of Virginia   (United States)

^c Borland Groover Clinic   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

^e UNIVERSITY OF OTAGO   (New Zealand)

^f South Florida Center of Gastroenterology   (United States)

^g ORLANDO IMMUNOLOGY CENTER   (United States)

^h GILEAD SCIENCES   (United States)

ⁱ ST VINCENT S HOSPITAL   (Australia)

^j JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GLUCOSE; INTERLEUKIN 28B; RIBAVIRIN; SOFOSBUVIR PLUS VELPATASVIR; TRIACYLGLYCEROL LIPASE; VELPATASVIR; VOXILAPREVIR; ANTIVIRUS AGENT; CARBAMIC ACID DERIVATIVE; DRUG COMBINATION; FUSED HETEROCYCLIC RINGS; SOFOSBUVIR; SOFOSBUVIR-VELPATASVIR DRUG COMBINATION;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; DYSPEPSIA; DYSPNEA; FATIGUE; FEMALE; HEADACHE; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 1 INFECTION; HEPATITIS C VIRUS GENOTYPE 1A INFECTION; HEPATITIS C VIRUS GENOTYPE 1B INFECTION; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 2 INFECTION; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 3 INFECTION; HUMAN; INSOMNIA; IRRITABILITY; LIVER FUNCTION TEST KIT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RASH; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SUSTAINED VIROLOGIC RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VIRAL UPPER RESPIRATORY TRACT INFECTION; ANTIVIRAL RESISTANCE; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG COMBINATION; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED;

ADULT; AGED; ANTIVIRAL AGENTS; CARBAMATES; DRUG COMBINATIONS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; HUMANS; MALE; MIDDLE AGED; RIBAVIRIN; SOFOSBUVIR;

EID: 85028350836     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.29256     Document Type: Article

References (10)

1. Holmes JA, Thompson AJ. Interferon-free combination therapies for the treatment of hepatitis C: current insights. Hepat Med 2015;7:51-70.
2. Lam BP, Jeffers T, Younoszai Z, Fazel Y, Younossi ZM. The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment. Therap Adv Gastroenterol 2015;8:298-312.
3. American Association for the Study of Liver Diseases/Infectious Diseases Society of America HCV Guidance Panel. HCV guidance: recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org. Accessed September 13, 2016.
4. Pawlotsky JM. Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology 2016;151:70-86.
5. Sarrazin C, Dvory-Sobol H, Svarovskaia ES, Doehle BP, Pang PS, Chuang SM, et al. Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir. Gastroenterology 2016;151:501-12.
6. Epclusa (sofosbuvir and velpatasvir) tablets, for oral use. Full prescribing information. Foster City, CA: Gilead Sciences, Inc.; 2016.
7. Foster GR, Afdhal N, Roberts SK, Brau N, Gane EJ, Pianko S, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 2015;373:2608-2617.
8. Feld JJ, Jacobson IM, Hezode C, Asselah T, Ruane PJ, Gruener N, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 2015;373:2599-2607.
9. Curry MP, O'Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 2015;373:2618-2628.
10. Feld JJ, Jacobson IM, Sulkowski MS, Poordad F, Tatsch F, Pawlotsky JM. Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection. Liver Int 2017;37:5-18.